Sourav Bhaduri1, Samantha Mills2, Mark Radon2, Michael Jenkinson3, and Harish Poptani1
1Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom, 2Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom, 3Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
1Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom, 2Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom, 3Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
We demonstrate the potential utility of DCE-MRI derived pharmacokinetic parameters in differentiating brain tumour types using the extended Tofts and the Shutter Speed Model.
Fig 1: Model fitting using A. extended Tofts and B. SSM in PCNSL. The same is shown for GBM in C and D. The original AIF curve is shown in yellow and its biexponential fit shown in black. The tissue uptake is shown in blue with its fitting shown in red.
Fig 2: Ktrans maps from the extended Tofts model from a patient with PCNSL (A), Gr III Glioma (B), GBM (C) and Metastasis (D). Box plots demonstrating the Ktrans (min-1, E), ve (F) and vp (G) values using extended Tofts model demonstrate highest values in metastasis, while PCNSL patients demonstrate lower values.